

NC Pharmacy Prior Approval Request for Triptans

Beneficiary Information

1. Beneficiary Last Name: _____ 2. First Name: _____
3. Beneficiary ID #: _____ 4. Beneficiary Date of Birth: _____ 5. Beneficiary Gender: _____

Prescriber Information

6. Prescribing Provider NPI #: _____
7. Requester Contact Information - Name: _____ Phone #: _____ Ext. _____

Drug Information

8. Drug Name: _____ 9. Strength: _____ 10. Quantity Per 30 Days: _____
11. Length of Therapy (in days): up to 30 days 60 Days 90 Days 120 Days 180 Days 365 Days Other _____

Clinical Information

Request for Non-Preferred Drug:

1. Failed two preferred drug(s). List preferred drugs failed: _____
1a. Allergic Reaction 1b. Drug-to-drug interaction. Please describe reaction: _____
2. Previous episode of an unacceptable side effect or therapeutic failure. Please provide clinical information:

3. Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to preferred drug(s). Please provide clinical information: _____
4. Age specific indications. Please give patient age and explain: _____
5. Unique clinical indication supported by FDA approval or peer reviewed literature. Please explain and provide a general reference:

6. Unacceptable clinical risk associated with therapeutic change. Please explain: _____

Request for Exceeding Quantity Limit (Exceeding 12 per 30 days):

7. Does the patient have a diagnosis of migraine or cluster headache? Yes No
8. Does the patient have more than 6 moderate or severe headache? Yes No
9. Does the patient have a history of NSAID therapy in the past year? Yes No
10. Does the patient have a contraindication or allergy to NSAID therapy? Yes No
11. Is the patient currently receiving therapy with a migraine preventative? Yes No
12. Does the patient have a contraindication or history of an adverse reaction with preventative medications? Yes No
Please list: _____
13. Did the patient have no clinical benefit after at least a 90 day trial of preventative medications at the maximum tolerated dose?
 Yes No
14. Has the patient been diagnosed with Ischemic Heart Disease, Peripheral Vascular Disease, Cerebrovascular Disease, Ischemic Bowel Disease, or Hemiplegic Migraine? Yes No
15. Has the patient received an MAO Inhibitor in the past 2 weeks? Yes No
16. Will the beneficiary have concurrent use of (or use within 24 hours) ergotamine-containing or ergot-type medication?
 Yes No
17. Will the beneficiary have concurrent use of (or use within 24 hours) another 5-HT₁ agonist? Yes No
18. Does the patient have uncontrolled hypertension or basilar migraine? Yes No
19. Has the prescriber reviewed the DHB evidenced-based recommendations on the treatment of migraine? Yes No

Signature of Prescriber: _____ Date: _____
(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.